[Outcomes of cetuximab combination chemotherapy in clinical practice for patients with metastatic colorectal cancer].
We aimed to evaluate the reproducibility of cetuximab combination chemotherapy as a standard treatment for patients with metastatic colorectal cancer in our hospital using actual clinical data. This study included 14, 9, and 4 patients who received third-line, second-line, and first-line treatment, respectively. The overall response rate(RR), progression-free survival( PFS), and overall survival(OS)were calculated according to treatment line and were compared with the results of largescale clinical studies. In patients undergoing third-line treatment, the RR was 14.3%, while the median PFS and OS were 2.9 and 9.6 months, respectively. These results were almost identical to those of the NCIC CTG CO. 17 study. In patients undergoing second-line treatment, the RR was 22.2% and the median PFS and OS were 5.8 and 7.1 months, respectively. These results were not inferior to those of the BOND study. In patients undergoing first-line treatment, partial response was observed in 75% of patients and stable disease was observed in 25% of patients. One patient subsequently underwent surgery. The RR(75%)was equal to that observed in the CRYSTAL study and the OPUS study. Standard treatment using cetuximab combination chemotherapy was found to be reproducible as third-line and second-line treatments in our clinical practice. Few patients received first-line treatment; hence, a larger number of patients will have to be evaluated in the future. Nevertheless, the administration of cetuximab combination chemotherapy may be appropriate as a medical treatment strategy for patients with metastatic colorectal cancer.